The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

The Role of FDG PET in Malignant Lymphoma

악성 림프종에서 FDG PET의 역할

  • Yun, Mi-Jin (Department of Nuclear medicine, Yonsei University Medical Center)
  • 윤미진 (연세대학교 의과대학 핵의학교실)
  • Published : 2002.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

FDG PET is a functional imaging modality whose ability to detect lesions is directly based on a change of the glycolytic metabolism of targeted tissues, may be advantageous over other techniques. Combined with excellent image qualify, high spatial resolution, and whole body imaging capability, it has become popular as a new approach in the evaluation of patients with various malignancies. Initial staging of nodal and extranodal lymphoma using FDG PET has been proven to be at least equal or superior to conventional imaging modalities. For the assessment of treatment responsiveness, FDG PET has a major impact on the management of patients in differentiating residual lymphoma from treatment related benign changes. Residual FDG uptake after the completion of chemotherapy is a good predictor of early relapse. However, it seems that the absence of FDG uptake in tumor mass may not exclude minimal residual disease causing later relapse. In the early evaluation of treatment response only after a few cycles of chemotherapy, FDG PET may have a promising role in identifying non-responders who could benefit from a different treatment strategy. At present, FDG PET appears to be the cost-effective, diagnostic modality of choice in the management of lymphoma patients. The role of FDG PET based-systems in terms of affecting long-term prognosis and survival benefit should be further elucidated in future prospective studios.

Keywords

References

  1. Warburg 0, Wind F, Negleis E. On the metabolism of tumors in the body. London: Constable; 1930. p254-70.
  2. Buchmann I, Reinhardt M, Elsner K, Bunjes D,Altehoefer C, Finke J, et al. 2-(fluorine-18)fluoro2-deoxy-D-glucose positron emission tomography inthe detection and staging of malignant lymphoma.A bicenter trial. Cancer 2001; 91: 889-99.
  3. Newman J, Francis I, Kaminski M, Wahl R.Imaging of lymphoma with PET with 2-[F-18]fluoro-2-deoxy-D-glucose: correlation with CT.Radiology 1994; 190: 111-6.
  4. Hoh C, Glaspy J, Rosen P, Dahlbom M, Lee S,Kunkel L, et al. Whole-body FDG-PET imaging forstaging of Hodgkin's disease and lymphoma. J NuclMed 1997; 38: 343-8.
  5. Moog F, Bangerter M, Diederichs C, Guhlmann A,Kotzerke J, Merkle E, et al. Lymphoma: role ofwhole-body 2-deoxy-2-[F-18]f1uoro-D-glucose(FDG) PET in nodal staging. Radiology 1997; 203:795-800.
  6. Stumpe K, Urbinelli M, Steinert H, Glanzmann C,Buck A, von Schulthess G. Whole-body positronemission tomography using fluorodeoxyglucose forstaging of lymphoma: effectiveness and comparisonwith computed tomography. Eur J Nucl Med 1998;25: 721-8.
  7. Jerusalem G, Warland V, Najjar F, Paulus P,Fassotte M, Fillet G, et al. Whole-body 18F-FDGPET for the evaluation of patients with Hodgkin'sdisease and non-Hodgkin's lymphoma. Nucl MedCommun 1999; 20: 13-20.
  8. Bangerter M, Kotzerke J, Griesshammer M, ElsnerK, Reske S, Bergmann L. Positron emission tomographywith 18-fluorodeoxyglucose in the staging andfollow-up of lymphoma in the chest. Acta Oncol1999; 38: 799-804.
  9. Kostakoglu L, Goldsmith S. Positron emission tomography in lymphoma: comparison with computed tomography and Gallium-67 single photon emission computed tomography. Clin Lymphoma 2000; 1: 67-74.
  10. Jerusalem G, Beguin Y, Fassotte M, Najjar F,Paulus P, Rigo P, et al. Whole-body positronemission tomography using l8F-fluorodeoxyglucosecompared to standard procedures for stagingpatients with Hodgkin's disease. Haematologiea2001; 86: 266-73.
  11. Hueltenschmidt B, Sautter-Bihl M, Lang 0, MaulF, Fischer J, Mergenthaler H, et al. Whole bodypositron emission tomography in the treatment ofHodgkin disease. Cancer 2001; 91: 302-10.
  12. Ingram C, Belli A, Lewars M, Reznek R, HusbandJ. Normal lymph node size in the mediastinum: aretrospective study in two patient groups. ClinRadiol 1989; 40: 35-9.
  13. Einstein D, Singer A, Chilcote W, Desai R.Abdominal lymphadenopathy: spectrum of CTfindings. Radiographies 1991; 11: 457-72.
  14. Anderson K, Leonard R, Canellos G, Skarin A, Kaplan W. High-dose gallium imaging in lymphoma. Am J Med Aug;(2): 1983; 75: 327-31.
  15. Gallamini A, Biggi A, Fruttero A, Pugno F,Cavallero G, Pregno P, et al. Revisiting theprognostic role of gallium scintigraphy in low-gradenon-Hodgkin's lymphoma. Eur J Nucl Med 1997;24: 1499-506.
  16. Okada J, Yoshikawa K, Imazeki K, Minoshima S,Uno K, Itami J, et al. The use of FDG-PET in thedetection and management of malignant lymphoma:correlation of uptake with prognosis. J Nucl Med1991; 32: 686-91.
  17. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995; 36:1790-6.
  18. Lapela M, Leskinen S, Minn H, Lindholm P, KlemiP, Soderstrom K, et al. Increased glucosemetabolism in untreated non-Hodgkin's lymphoma:a study with positron emission tomography andfluorine-18-fluorodeoxyglucose. Blood Nov 1;(9):1995; 86: 3522-7.
  19. Najjar F, Hustinx R, Jerusalem G, Fillet G, Rigo P.Positron emission tomography (PET) for staginglow-grade non-Hodgkin's lymphomas (NHL).Cancer Biother Radiopharm 2001; 16: 297-304.
  20. Reske S, Kotzerke 1. FDG-PET for clinical use.Results of the 3rd German InterdisciplinaryConsensus Conference, "Onko-PET III", 21 Julyand 19 September 2000. Eur J Nucl Med 2001; 28:1707-23.
  21. Jerusalem G, Beguin Y, Najjar F, Hustinx R,Fassotte M, Rigo P, et al. Positron emissiontomography (PET) with 18F-fluorodeoxyglucose(18F-FDG) for the staging of low-grade nonHodgkin'slymphoma (NHL). Ann Oneol 2001; 12:825-30.
  22. Talbot J, Haioun C, Rain J, Meignan M, WiolandM, Misset J, et al. [18F]-FDG positron imaging inclinical management of lymphoma patients. CritRev Oneol Hematol 2001; 38: 193-221.
  23. Fishman E, Kuhlman J, Jones R. CT of lymphoma: spectrum of disease. Radiographies 1991; 11: 647-69.
  24. Skovsgaard T, Brinckmeyer L, Vesterager L,Thiede T, Nissen N. The liver in Hodgkin'sdisease--II. Histopathologic findings. Eur J CancerClin Oneol 1982; 18: 429-35.
  25. Ahmann D, Kiely J, Harrison EJ, Payne W.Malignant lymphoma of the spleen. A review of 49cases in which the diagnosis was made atsplenectomy. Cancer 1966; 19: 461-9.
  26. Castellino R. Imaging techniques for staging abdominal Hodgkin's disease. Cancer Treat Rep 1982; 66: 697-700.
  27. Castellino R, Hoppe R, Blank N, Young S,Neumann C, Rosenberg S, et al. Computedtomography, lymphography, and staging laparotomy:correlations in initial staging of Hodgkin disease.AJR 1984; 143: 37-41.
  28. Mansfield C, Fabian C, Jones S, Van Slyck E, Grozea P, Morrison F, et al. Comparison of lymphangiography and computed tomography scanning in evaluating abdominal disease in stages III and IV Hodgkin's disease. A Southwest Oncology Group study. Cancer 1990; 66: 2295-9.
  29. Munker R, Stengel A, Stabler A, Hiller E, BrehmG. Diagnostic accuracy of ultrasound and computedtomography in the staging of Hodgkin's disease.Verification by laparotomy in 100 cases. Cancer1995; 76: 1460-6.
  30. Harisinghani M, Saini S, Weissleder R, Rubin D,deLange E, Harms S, et al. Splenic imaging withultrasmall superparamagnetic iron oxide ferumoxtran10(AMI-7227): preliminary observations. J ComputAssist Tomogr 2001; 25: 770-6.
  31. Moog F, Bangerter M, Kotzerke J, Guhlmann A,Frickhofen N, Reske S. 18-F-fluorodeoxyglucosepositronemission tomography as a new approach todetect lymphomatous bone marrow. J Clin Oncol1998; 16: 603-9.
  32. Sugawara Y, Zasadny K, Kison P, Baker L, WahlR. Splenic fluorodeoxyglucose uptake increased bygranulocyte colony-stimulating factor therapy: PETimaging results. J Nucl Med 1999; 40: 1456-62.
  33. Kim C, Reske S, Alavi A. Bone marrow scintigraphy. Saint Louis: Mosby; 1995.
  34. Papac R. Bone marrow metastases: a review. Cancer 1994; 74: 2403-13.
  35. Munker R, Hasenclever D, Brosteanu 0, Hiller E,Diehl V. Bone marrow involvement in Hodgkin'sdisease: an analysis of 135 consecutive cases.German Hodgkin's Lymphoma Study Group. J ClinOncol 1995; 13: 403-9.
  36. Bonner H. The blood and the lymphoid organs. Philadelphia: Lipinkott; 1988.
  37. Hoane B, Shields A, Porter B, Shulman H. Detectionof lymphomatous bone marrow involvement withmagnetic resonance imaging. Blood 1991; 78:728-38.
  38. McKenna R. The bone marrow manifestations ofHodgkin's disease, the non-Hodgkin's lymphomas,and lymphoma-like disorders. Baltimore: Williams& Wilkins; 1992. pl135.
  39. Altehoefer C, Blum U, Bathmann J, Wustenberg C,Uhrmeister P, Laubenberger J, et al. Comparative diagnostic accuracy of magnetic resonance imagingand immunoscintigraphy for detection of bonemarrow involvement in patients with malignantlymphoma. J Clin Oncol 1997; 15: 1754-60.
  40. Linden A, Zankovich R, Theissen P, Diehl V,Schicha H. Malignant lymphoma: bone marrowimaging versus biopsy. Radiology 1989; 173: 335-9.
  41. Moog F, Kotzerke J, Reske S. FDG PET canreplace bone scintigraphy in primary staging ofmalignant lymphoma. J Nucl Med 1999; 40:1407-13.
  42. Carr R, Barrington S, Madan B, O'Doherty M,Saunders C, van der Walt J, et al. Detection oflymphoma in bone marrow by whole-body positronemission tomography. Blood 1998; 91: 3340-6.
  43. Kostakoglu L, Goldsmith S. Fluorine-18 fluorodeoxyglucosepositron emission tomography in thestaging and follow-up of lymphoma: is it time toshift gears? Eur J Nucl Med 2000; 27: 1564-78.
  44. Hoffman J, Waskin H, Schifter T, Hanson M, GrayL, Rosenfeld S, et al. FDG-PET in differentiatinglymphoma from nonmalignant central nervoussystem lesions in patients with AIDS. J Nucl Med1993; 34: 567-75.
  45. Villringer K, Jager H, Dichgans M, Ziegler S,Poppinger J, Herz M, et al. Differential diagnosisof CNS lesions in AIDS patients by FDG-PET. JComput Assist Tomogr 1995; 19: 532-6.
  46. Heald A, Hoffman J, Bartlett J, Waskin H.Differentiation of central nervous system lesions inAIDS patients using positron emission tomography(PET). Int J STD AIDS 1996; 7: 337-46.
  47. O'Doherty M, Barrington S, Campbell M, Lowe J,Bradbeer C. PET scanning and the humanimmunodeficiency virus-positive patient. J NuclMed 1997; 38: 1575-83.
  48. Surbone A, Longo D, DeVita VJ, Ihde D, Duffey P,Jaffe E, et al. Residual abdominal masses inaggressive non-Hodgkin's lymphoma after combinationchemotherapy: significance and management. J ClinOneal 1988; 6: 1832-7.
  49. Smith D, Shaffer K, Kim D, Canellos G, Mauch P, Shulman L. Mediastinal large cell lymphoma: prognostic significance of CT findings at presentation and after treatment. Oncology 1998;55: 284-8.
  50. McLaughlin A, Magee M, Greenough R, Allman K,Southee A, Meikle S, et al. Current role of galliumscanning in the management of lymphoma. Eur JNucl Med 1990; 16: 755-71.
  51. Zinzani P, Zompatori M, Bendandi M, Battista G,Fanti S, Barbieri E, et al. Monitoring bulkymediastinal disease with gallium-67, CT-scan andmagnetic resonance imaging in Hodgkin's diseaseand high-grade non-Hodgkin's lymphoma. LeukLymphoma 1996; 22: 131-5.
  52. Vose J, Bierman P, Anderson J, Harrison K,Dalrymple G, Byar K, et al. Single-photon emissioncomputed tomography gallium imaging versuscomputed tomography: predictive value in patientsundergoing high-dose chemotherapy and autologousstem-cell transplantation for non-Hodgkin's lymphoma.J Clin Oneol 1996; 14: 2473-9.
  53. Janicek M, Kaplan W, Neuberg D, Canellos G,Shulman L, Shipp M. Early restaging gallium scanspredict· outcome in poor-prognosis patients withaggressive non-Hodgkin's lymphoma treated withhigh-dose CHOP chemotherapy. J Clin Oneol 1997;15: 1631-7.
  54. Front D, Bar-Shalom R, Mor M, Haim N, EpelbaumR, Frenkel A, et al. Aggressive non-Hodgkinlymphoma: early prediction of outcome with 67Gascintigraphy. Radiology 2000; 214: 253-7.
  55. Hoekstra 0, Ossenkoppele G, Golding R, vanLingen A, Visser G, Teule G, et al. Early treatmentresponse in malignant lymphoma, as determined byplanar fluorine-18-fluorodeoxyglucose scintigraphy.J Nucl Med 1993; 34: 1706-10.
  56. Romer W, Hanauske A, Ziegler S, Thodtmann R,Weber W, Fuchs C, et al. Positron emissiontomography in non-Hodgkin's lymphoma:assessment of chemotherapy with fluorodeoxyglucose.Blood 1998; 91: 4464-71.
  57. Jerusalem G, Beguin Y, Fassotte M, Najjar F, Paulus P, Rigo P, et al. Whole-body positronemission tomography using 18F-fluorodeoxyglucosefor posttreatment evaluation in Hodgkin's diseaseand non-Hodgkin's lymphoma has higher diagnosticand prognostic value than classical computedtomography scan imaging. Blood 1999; 94: 429-33.
  58. Jerusalem G, Beguin Y, Fassotte M, Najjar F,Paulus P, Rigo P, et al. Persistent tumor 18F-FDGuptake after a few cycles of polychemotherapy ispredictive of treatment failure in non-Hodgkin'slymphoma. Haematologiea 2000; 85: 613-8.
  59. Mikhaeel N, Timothy A, O'Doherty M, Hain S,Maisey M. 18-FDG-PET as a prognostic indicatorin the treatment of aggressive Non-Hodgkin'sLymphoma-comparison with CT. Leuk Lymphoma2000; 39: 543-53.
  60. Cremerius U, Fabry U, Neuerburg J, Zimny M,Osieka R, Buell U. Positron emission tomographywith 18F-FDG to detect residual disease aftertherapy for malignant lymphoma. Nucl MedCommun 1998; 19: 1055-63.
  61. Spaepen K, Stroobants S, Dupont P, Thomas J,Vandenberghe P, Balzarini J, et al. Can positronemission tomography with [(18)F]-fluorodeoxyglucoseafter first-line treatment distinguish Hodgkin'sdisease patients who need additional therapy fromothers in whom additional therapy would meanavoidable toxicity? Br J Haematol 2001; 115: 272-8.
  62. Spaepen K, Stroobants S, Dupont P, VanSteenweghen S, Thomas J, Vandenberghe P, et al.Prognostic value of positron emission tomography(pET) with fluorine-18 fluorodeoxyglucose ([18F]FDG)after first-line chemotherapy in non-Hodgkin'slymphoma: is [18F]FDG-PET a valid alternative toconventional diagnostic methods? J Clin Oneol2001; 19: 414-9.
  63. Hollinger E, Alibazoglu H, Ali A, Green A,Lamonica G. Hematopoietic cytokine-mediatedFDG uptake simulates the appearance of diffusemetastatic disease on whole-body PET imaging.Clin Nucl Med 1998; 23: 93-8.
  64. Yao W, Hoh C, Hawkins R, Glaspy J, Weil J, LeeS, et al. Quantitative PET imaging of bone marrowglucose metabolic response to hematopoieticcytokines. J Nucl Med 1995; 36: 794-9.
  65. Rini J, Leonidas J, Tomas M, Chen B, KaraylcinG, Palestro C. 18F-FDG Uptake in the AnteriorMediastinum. Physiologic Thymic Uptake orDisease? Clin Positron Imaging 2000; 3: 115-25.
  66. Brink I, Reinhardt M, Hoegerle S, Altehoefer C,Moser E, Nitzsche E. Increased metabolic activityin the thymus gland studied with l8F-FDG PET:age dependency and frequency after chemotherapy.J Nucl Med 2001; 42: 591-5.